Screener
Stoke Therapeutics, Inc. STOK Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 6 | 5 |
| Additional paid-in capital | 942,704 | 849,624 |
| Accumulated other comprehensive (loss) income | (115) | 543 |
| Accumulated deficit | (547,718) | (497,715) |
| Total stockholders’ equity | $394,877 | $352,457 |
| Total liabilities and stockholders’ equity | $443,277 | $418,434 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s retained earnings?
- Stoke Therapeutics, Inc. (STOK) reported retained earnings of -$547.72M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s retained earnings changed year-over-year?
- Stoke Therapeutics, Inc.'s retained earnings decreased by 44.9% year-over-year, from -$377.95M to -$547.72M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s retained earnings has grown at a 35.2% compound annual growth rate (CAGR), from -$110.28M to -$497.72M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Stoke Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude